Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Squamous Cell Carcinoma of the Head and Neck (US/EU)
The angiogenesis inhibitor Erbitux, in combination with platinum-based therapy and 5-fluorouracil (5-FU), was the standard treatment option for all squamous cell carcinoma of the head and neck (SCCHN) patients in the first-line recurrent or metastatic setting. The approval of immune checkpoint inhibitors—Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb)—in the first-line setting over the last decade has changed the treatment paradigm for recurrent or metastatic SCCHN patients as monotherapy and/or in combination with platinum + 5-FU. However, there is a strong need for effective therapies in this patient setting. This report provides a detailed analysis of the factors that influence medical oncologists’ prescribing decisions and reviews the unmet needs that novel therapies should confront.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in medical oncologists’ prescribing decisions for non-nasopharyngeal SCCHN?
- How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunity that drug developers could leverage in the treatment of non-nasopharyngeal SCCHN?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical target product profile for non-nasopharyngeal SCCHN?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 33 European medical oncologists fielded in December 2021
Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly
Key drugs: Erbitux, Keytruda, Opdivo
Table of contents
- Squamous Cell Carcinoma of the Head and Neck - Unmet Need - Unmet Need - Squamous Cell Carcinoma of the Head and Neck (US/EU)
- Unmet Need - Recurrent or Metastatic Non-Nasopharyngeal SCCHN - TPP Simulator - March 2022
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN
- Importance of efficacy attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Importance of safety and tolerability attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Importance of safety and tolerability attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Importance of convenience of administration attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Overall Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Mean overall performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN: United States and Europe
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select efficacy attributes: United States
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select efficacy attributes: Europe
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Safety and Tolerability Attributes: United States
- Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select safety and tolerability attributes: Europe
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Convenience of Administration Attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in recurrent or metastatic non-nasopharyngeal SCCHN
- Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
- Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
- Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in recurrent or metastatic non-nasopharyngeal SCCHN: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
- Key findings: unmet need in recurrent or metastatic non-nasopharyngeal SCCHN and related indications
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Recurrent or Metastatic Non-Nasopharyngeal SCCHN and Related Indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in recurrent or metastatic non-nasopharyngeal SCCHN and related indications: Europe
- Opportunity analysis
- Target product profiles
- Appendix
Related Market Assessment Reports
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
